Oridonin (NSC-250682)

For research use only.

Catalog No.S2335 Synonyms: Isodonol, Rubescenin

15 publications

Oridonin (NSC-250682) Chemical Structure

CAS No. 28957-04-2

Oridonin (Isodonol, Rubescenin, NSC-250682), a diterpenoid purified from Rabdosia rubescens, is a traditional agent with antitumor, anti-bacterial and anti-inflammatory effects. Oridonin inhibits AKT1 and AKT2 kinase activity with IC50 of 8.4 μM and 8.9 μM, respectively.

Selleck's Oridonin (NSC-250682) has been cited by 15 publications

1 Customer Review

  • Histopathological analysis of H460 tumors following combination treatment with oridonin and radiation. Hematoxylin and eosin (H-E) staining and immunohistochemistry for cleaved caspase-3 and γ-H2AX were performed on tumors harvested at 14 days after IR. Representative images of H-E-stained tumors (upper images) and cleaved caspase-3- and γ-H2AX-positive cells (middle images, brown staining) and quantification of cleaved caspase-3 and γ-H2AX-positive staining with six mice in each group (lower plots, means ± SEM) are shown; * p < 0.05.

    Int J Mol Sci, 2018, 19(8). Oridonin (NSC-250682) purchased from Selleck.

Purity & Quality Control

Choose Selective Akt Inhibitors

Biological Activity

Description Oridonin (Isodonol, Rubescenin, NSC-250682), a diterpenoid purified from Rabdosia rubescens, is a traditional agent with antitumor, anti-bacterial and anti-inflammatory effects. Oridonin inhibits AKT1 and AKT2 kinase activity with IC50 of 8.4 μM and 8.9 μM, respectively.
Targets
Akt1 [5]
(Cell-free assay)
Akt2 [5]
(Cell-free assay)
8.4 μM 8.9 μM
In vitro

Oridonin effectively inhibites the proliferation of a wide variety of cancer cells including those from prostate (LNCaP, DU145, PC3), breast (MCF-7, MDA-MB231), non-small cell lung (NSCL) (NCI-H520, NCI-H460, NCI-H1299) cancers, acute promyelocytic leukemia (NB4), and glioblastoma multiforme (U118, U138) with ED50s ranging from 1.8 to 7.5 μg/ml. [1] The antitumor activities of Oridonin may due to its inhibitory effects on NF-kappaB and MAPKs signal pathways. [2] [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HL60 Ml72R5l1d3SxeHnjbZR6KGG|c3H5 MUe0PEBpenN? MUnDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIUFYxKGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;Mj61{txO NXrUdHhJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4NVk5PzFpPkKzPFE6QDdzPD;hQi=>
RAW264.7 MV7BcpRqcW6obHHtcYF1d3K7IHHzd4F6 M{TlOlE5KGi{cx?= M3;iUGFvfGmrbn\sZY1u[XSxcomgZYN1cX[rdImgbY4hdW:3c3WgVmFYOjZ2LkegZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCOUGOtbY5lfWOnZDDubZRzcWNib4jp[IUheHKxZIXjeIlwdiCjZoTldkAyQCCqcoOgZpkhT3KrZYPzJI1mfGixZDygTWM2OD13LkNOwG0> M3;aU|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|OEG5PFcyLz5{M{ixPVg4OTxxYU6=
K562 Mle4RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? MlfXO|IhcHK| M2q5W2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iS{W2NkBk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR|UxRTRwM{ROwG0> MortQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjhzNkW3N|goRjJ6MU[1O|M5RC:jPh?=
Bel7402 NEPUelBCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= MVe3NkBpenN? NYjPPYhCSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDC[Yw4PDB{IHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9OU41Oc7:TR?= MoraQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjhzNkW3N|goRjJ6MU[1O|M5RC:jPh?=
MGC803 Ml7ORY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? NFzkeHU4OiCqcoO= MnTsRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCPR1O4NFMh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD17LkC2{txO NWLNN3hwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkixOlU4OzhpPkK4NVY2PzN6PD;hQi=>
KB/CP4 MlyyRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? NInaS|c1QCCqcoO= M1KyV2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iS1KvR3A1KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MUCuPO69VQ>? NID2WG89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEG2OVc{QCd-MkixOlU4Ozh:L3G+
KB-3-1 MUnBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? MnP6OFghcHK| NHfhWplCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFvCMVMuOSClZXzsd{Bi\nSncjC0PEBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUGzMlI1|ryP NFvYVG89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEG2OVc{QCd-MkixOlU4Ozh:L3G+
BEL7404/CP20 MXrBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? M3nve|Q5KGi{cx?= NXrMenEzSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDCSWw4PDB2L1PQNlAh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1zNz6xO:69VQ>? M1nTVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MU[1O|M5Lz5{OEG2OVc{QDxxYU6=
MCF7 NVvoWINNSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= NVjybFZHPzJiaILz NVGwcWtbSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MUeuPFnPxE1? MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDF4NUezPEc,OjhzNkW3N|g9N2F-
Bel7404 NFXyeZJCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= MnH1OFghcHK| Mlq0RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCEZXy3OFA1KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MUeuPVLPxE1? NXXSdmltRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkixOlU4OzhpPkK4NVY2PzN6PD;hQi=>
NCI-H460 NXXTW2ZPSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= NXT5[4RlPDhiaILz NELIUJhCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF7DTU1JPDZyIHPlcIx{KGGodHXyJFQ5KGi{czDifUBOXFRiYYPzZZktKEmFNUC9NlAvPTIQvF2= Mn\DQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjhzNkW3N|goRjJ6MU[1O|M5RC:jPh?=
NCI-H460/MX20 NULkb5dwSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= MYi0PEBpenN? NX;QRWRWSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDOR2kuUDR4MD;NXFIxKGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MkWuPFbPxE1? NITpU5A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEG2OVc{QCd-MkixOlU4Ozh:L3G+
K562 NHPpeWpCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= NHWyUXo4OiCqcoO= Ml7pRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCNNU[yJINmdGy|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiClZXzsJJZq[WKrbHn0fUBi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUSuOlTPxE1? NEDsWm89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEmyNVc2Pyd-M{C5NlE4PTd:L3G+
SGC7901 M3\SXWFvfGmycn;sbYZmemG2aY\lJIF{e2G7 NHjxVXk4OiCqcoO= NY\wSnpwSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDTS2M4QTBzIHPlcIx{KGG|c3Xzd4VlKGG|IILl[JVkfGmxbjDpckBk\WyuII\pZYJqdGm2eTDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR|UxRTdwMUROwG0> NIDiZoY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEmyNVc2Pyd-M{C5NlE4PTd:L3G+
Bel7402 M36yb2FvfGmycn;sbYZmemG2aY\lJIF{e2G7 M1z0XFczKGi{cx?= Mn7ORY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCEZXy3OFAzKGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjDj[YxtKH[rYXLpcIl1gSCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVcvQDYQvF2= MoKxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB7MkG3OVcoRjNyOUKxO|U4RC:jPh?=
HL60 MoHBRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? NIqwNYg4OiCqcoO= NHXQPY9CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjMOlAh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKGmwIHPlcIwhfmmjYnnsbZR6KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9PU41Ps7:TR?= NITCO5I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEmyNVc2Pyd-M{C5NlE4PTd:L3G+
PC3 NYHuZ4dRSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= MkfyO|IhcHK| NXvXSJM1SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDQR|Mh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKGmwIHPlcIwhfmmjYnnsbZR6KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9NVAvODgQvF2= NYTxTFBSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{C5NlE4PTdpPkOwPVIyPzV5PD;hQi=>
A549 NVPQUWlNSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= MlfaO|IhcHK| MVXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEF3NEmgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKGOnbHygeoli[mmuaYT5JIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MUiuNVXPxE1? NEjtTVc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEmyNVc2Pyd-M{C5NlE4PTd:L3G+
L02 M33Hd2N6fG:2b4jpZ4l1gSCjc4PhfS=> NVj4O291PzJiaILz MWTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDMNFIh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKGmwIHPlcIwhfmmjYnnsbZR6KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9NVkvPTQQvF2= MkL4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB7MkG3OVcoRjNyOUKxO|U4RC:jPh?=
HCT116 M1[1S2FvfGmycn;sbYZmemG2aY\lJIF{e2G7 M3:1VlQ5KGi{cx?= NF\hdFJCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjDWFEyPiClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gZ4VtdCC4aXHibYxqfHliaX7jeYJifGWmIH\vdkA1QCCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVYvQDUQvF2= MnXRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB7OEGxNVMoRjNyOUixNVE{RC:jPh?=
L02 NED2UIpEgXSxdH;4bYNqfHliYYPzZZk> M3;QWFQ5KGi{cx?= MoTBR5l1d3SxeHnjbZR6KGmwIHj1cYFvKExyMjDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4h[2WubDD2bYFjcWyrdImgbY5kfWKjdHXkJIZweiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR|UxRTZwOUhOwG0> MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODl6MUGxN{c,OzB7OEGxNVM9N2F-
Bel7402 M4fsbmFvfGmycn;sbYZmemG2aY\lJIF{e2G7 MXS0PEBpenN? MmDCRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCEZXy3OFAzKGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjDj[YxtKH[rYXLpcIl1gSCrbnP1ZoF1\WRiZn;yJFQ5KGi{czDifUBOXFRiYYPzZZktKEmFNUC9PU42Qc7:TR?= MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODl6MUGxN{c,OzB7OEGxNVM9N2F-
MCF7 M2nkV2FvfGmycn;sbYZmemG2aY\lJIF{e2G7 NY\yPJlDPDhiaILz NXHnNJJQSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjDj[YxtKH[rYXLpcIl1gSCrbnP1ZoF1\WRiZn;yJFQ5KGi{czDifUBOXFRiYYPzZZktKEmFNUC9NVcvPTcQvF2= NIL1[Ys9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEm4NVEyOyd-M{C5PFEyOTN:L3G+
MDA-MB-231 MlvDRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? NHf2OGs1QCCqcoO= NIHIWm9CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3ERU1OSi1{M{GgZ4VtdHNiaX7jeYJifGWmIH\vdkA1QCCqcoOgZpkhVVSWIHHzd4F6NCCHQ{WwQVI6NjUQvF2= M1O1WlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyOUixNVE{Lz5|MEm4NVEyOzxxYU6=
HCT116 MnjPR4VtdCCleXPs[UBienKnc4SgZZN{[Xl? NE[zOIc{KHWP MlnSNlQhcHK| MXXJcoR2[3Srb36gbY4h[2WubDDjfYNt\SCjcoLld5QhcW5iaIXtZY4hUEOWMUG2JINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hcW5iY4njcIlvKEFicILveIVqdiCneIDy[ZN{cW:wIHzleoVtKGG2IEOgeW0hcW6ldXLheIVlKG[xcjCyOEBpenNiYomgW4V{fGW{bjDicI91KGGwYXz5d4l{ M3rZVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyOUixNVE{Lz5|MEm4NVEyOzxxYU6=
HCT116 MlXSR4VtdCCleXPs[UBienKnc4SgZZN{[Xl? MYSzJJVO NYLrXpFVOjRiaILz NV;qTVNlUW6mdXP0bY9vKGmwIHPlcIwh[3mlbHWgZZJz\XO2IHnuJIh2dWGwIFjDWFEyPiClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIHnuJIN6[2yrbjDCNUBxem:2ZXnuJIV5eHKnc4Ppc44hdGW4ZXygZZQhOyC3TTDpcoN2[mG2ZXSg[o9zKDJ2IHjyd{BjgSCZZYP0[ZJvKGKub4SgZY5idHm|aYO= MoX4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB7OEGxNVMoRjNyOUixNVE{RC:jPh?=
HCT116 NFrtVpFCeG:ydH;0bYMh[XO|YYm= M2S1dlEhfU1? NFT1T3czPCCqcoO= MnzvTY5lfWO2aX;uJI9nKGGyb4D0c5Rq[yCvb4LwbI9td2erY3HsJINp[W6pZTDpckBpfW2jbjDIR3QyOTZiY3XscJMh[XO|ZYPz[YQh[XNibH;zd{Bw\iCxcnnnbY5idCCvb4LwbI9td2e7IHH0JFEhfU1iaX7jeYJifGWmIH\vdkAzPCCqcoOgZpkhcGGnbXH0c5h6dGmwLXXvd4lvKHO2YXnubY5oKGKjc3XkJI1q[3Kxc3PvdIlkKG2ndHjv[C=> M1jib|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyOUixNVE{Lz5|MEm4NVEyOzxxYU6=
HCT116 MXLBdI9xfG:2aXOgZZN{[Xl? MWKxJJVO MX6yOEBpenN? MkLpTY5lfWO2aX;uJI9nKGGyb4D0c5Rq[yCvb4LwbI9td2erY3HsJINp[W6pZTDpckBpfW2jbjDIR3QyOTZiY3XscJMh[XO|ZYPz[YQh[XNiZn;ycYF1cW:wIH;mJJVve3S{dXP0eZJm\CC|dHH0[UBifCBzIIXNJIlv[3WkYYTl[EBnd3JiMkSgbJJ{KGK7IHjh[Y1ifG:6eXzpck1md3OrbjDzeIFqdmmwZzDiZZNm\CCvaXPyc5Nkd3CrYzDt[ZRpd2R? M2\oUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyOUixNVE{Lz5|MEm4NVEyOzxxYU6=
HCT116 NGLxTHVCeG:ydH;0bYMh[XO|YYm= MVyxJJVO M3e4TVI1KGi{cx?= M3jLb2lv\HWldHnvckBw\iCjcH;weI91cWNibX;ydIhwdG:paXPhcEBkcGGwZ3WgbY4hcHWvYX6gTGNVOTF4IHPlcIx{KGG|c3Xzd4VlKGG|IH\vdo1ifGmxbjDv[kB3d2y3bXWgd5dmdGyrbnegZZQhOSC3TTDpcoN2[mG2ZXSg[o9zKDJ2IHjyd{BjgSCqYXXtZZRwgHmuaX6t[Y9{cW5ic4ThbY5qdmdiYnHz[YQhdWmlcn;zZ49xcWNibXX0bI9l NX3FZWYzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{C5PFEyOTNpPkOwPVgyOTF|PD;hQi=>
HCT116 MkG2RZBweHSxdHnjJIF{e2G7 M1rhVFEhfU1? M3nZWlI1KGi{cx?= NEX5OopKdmS3Y4Tpc44hd2ZiYYDvdJRwfGmlIH3vdpBpd2yxZ3njZYwh[2ijbnflJIlvKGi3bXHuJGhEXDFzNjDj[YxteyCjc4Pld5Nm\CCjczDmc5Ju[XSrb36gc4Yh[2:wZHXud4VlKG63Y3zlbUBifCBzIIXNJIlv[3WkYYTl[EBnd3JiMkSgbJJ{KGK7IHjh[Y1ifG:6eXzpck1md3OrbjDzeIFqdmmwZzDiZZNm\CCvaXPyc5Nkd3CrYzDt[ZRpd2R? M37S[|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyOUixNVE{Lz5|MEm4NVEyOzxxYU6=
HCT116 Mn;oRZBweHSxdHnjJIF{e2G7 NFPxTlEyKHWP MYOyOEBpenN? MXrJcoR2[3Srb36gc4Yh[XCxcITveIlkKG2xcoDoc4xw\2mlYXygZ4hidmenIHnuJIh2dWGwIFjDWFEyPiClZXzsd{Bie3Onc4Pl[EBieyClZXzsJIx6e2m|IHH0JFEhfU1iaX7jeYJifGWmIH\vdkAzPCCqcoOgZpkhcGGnbXH0c5h6dGmwLXXvd4lvKHO2YXnubY5oKGKjc3XkJI1q[3Kxc3PvdIlkKG2ndHjv[C=> M{X6XVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyOUixNVE{Lz5|MEm4NVEyOzxxYU6=
HCT116 M{nCdGFxd3C2b4TpZ{Bie3OjeR?= NGq3W5EyKHWP NXiycVFKOjRiaILz M2nGSGlv\HWldHnvckBw\iCjcH;weI91cWNibX;ydIhwdG:paXPhcEBkcGGwZ3WgbY4hcHWvYX6gTGNVOTF4IHPlcIx{KGG|c3Xzd4VlKGG|IH3lcYJz[W6nIIPodolvc2GpZTDheEAyKHWPIHnuZ5Vj[XSnZDDmc5IhOjRiaILzJIJ6KGijZX3heI95gWyrbj3lc5NqdiC|dHHpcolv\yCkYYPl[EBucWO{b4Pjc5Bq[yCvZYToc4Q> MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODl6MUGxN{c,OzB7OEGxNVM9N2F-
PLC/PRF/5 NYf4TYFtSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= MmjkO|IhcHK| NYjpd|EzSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDQUGMwWFKIL{WgZ4VtdHNiaX7jeYJifGWmIH\vdkA4OiCqcoOgZpkhS0ONODDj[YxteyxiSVO1NF04NjRzzszN NFTt[JQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MUKwNFI{QCd-M{GyNFAzOzh:L3G+
HepG2 MXPBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? MVO3NkBpenN? NGPZR4xCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjldGczKGOnbHzzJIlv[3WkYYTl[EBnd3JiN{KgbJJ{KGK7IFPDT|gh[2WubIOsJGlEPTB;OD6xNu69VQ>? NV32XpB7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{GyNFAzOzhpPkOxNlAxOjN6PD;hQi=>
RPMI8226 MoHKRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? M3LNZVczKGi{cx?= NFPZeoRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGLQUWk5OjJ4IHPlcIx{KGmwY4XiZZRm\CCob4KgO|IhcHK|IHL5JGNEUzhiY3XscJMtKEmFNUC9PU4zPc7:TR?= NGKzSXM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MUKwNFI{QCd-M{GyNFAzOzh:L3G+
LO2 NGT1PXdEgXSxdH;4bYNqfHliYYPzZZk> MXu3NkBpenN? NV3RWmw{S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVE9{IHPlcIx{KGmwY4XiZZRm\CCob4KgO|IhcHK|IHL5JGNEUzhiY3XscJMtKEmFNUC9NVcvPDgQvF2= NFvhTVY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MUKwNFI{QCd-M{GyNFAzOzh:L3G+
A549 MlPDRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? NFfzd284OiCqcoO= MXPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEF3NEmgZ4VtdHNiaX7jeYJifGWmIH\vdkA4OiCqcoOgZpkhS0ONODDj[YxteyxiSVO1NF0{OC52zszN NEfudWg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MUKwNFI{QCd-M{GyNFAzOzh:L3G+
HepG2 NXPj[WU2TnWwY4Tpc44h[XO|YYm= M3\hc|AvOSC2bzCxJJVO NXLpS5B3OTBiZHH5dy=> MlTsTY5pcWKrdHnvckBw\iClb3zvcpkh\m:{bXH0bY9vKGmwIHj1cYFvKEincFeyJINmdGy|IHH0JFAvOSC2bzCxJJVOKGmwY4XiZZRm\CCob4KgNVAh\GG7czDifUBkenm|dHHsJJZqd2yndDDzeIFqdmmwZzDiZZNm\CCvaXPyc5Nkd3CrYzDt[ZRpd2R? MnjUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzF{MECyN|goRjNzMkCwNlM5RC:jPh?=
PLC/PRF/5 MojySpVv[3Srb36gZZN{[Xl? M1fofVAvODBzIITvJFEhfU1? M{\wUFExKGSjeYO= MmHJTY5pcWKrdHnvckBw\iClb3zvcpkh\m:{bXH0bY9vKGmwIHj1cYFvKFCOQz;QVmYwPSClZXzsd{Bie3Onc4Pl[EBieyCmZXPy[YF{\SCrbjDjc4xwdnlic3n6[UBifCByLkCwNUB1dyBzIIXNJIlv[3WkYYTl[EBnd3JiMUCg[IF6eyCkeTDjdpl{fGGuII\pc4xmfCC|dHHpcolv\yCkYYPl[EBucWO{b4Pjc5Bq[yCvZYToc4Q> MnvWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzF{MECyN|goRjNzMkCwNlM5RC:jPh?=
K562 NFzVeFlCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= MlTMO|IhcHK| NIPXfYtCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFu1OlIh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKGmwIHPlcIwhfmmjYnnsbZR6KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9OE44Qc7:TR?= NEWzVW49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MUKwNlk6Oid-M{GyNFI6QTJ:L3G+
SGC7901 MXzBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? MYq3NkBpenN? NGnlPWNCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGPHR|c6ODFiY3XscJMh[XO|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJINmdGxidnnhZoltcXS7IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:Py56N988US=> NVXxRmpvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{GyNFI6QTJpPkOxNlAzQTl{PD;hQi=>
Bel7402 M4LRdmFvfGmycn;sbYZmemG2aY\lJIF{e2G7 M3yybVczKGi{cx?= Mn;YRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCEZXy3OFAzKGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjDj[YxtKH[rYXLpcIl1gSCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVgvOzIQvF2= NU\3eW53RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{GyNFI6QTJpPkOxNlAzQTl{PD;hQi=>
A549 MYjBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? M2CwTFczKGi{cx?= NXvuSYZ2SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjDj[YxtKH[rYXLpcIl1gSCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVE4NjkQvF2= NILodIE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MUKwNlk6Oid-M{GyNFI6QTJ:L3G+
L02 M{m0WWN6fG:2b4jpZ4l1gSCjc4PhfS=> M4DC[VczKGi{cx?= NH;PU|ZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBNODJiY3XscJMh[XO|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJINmdGxidnnhZoltcXS7IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:OThwNklOwG0> NF3kV4Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MUKwNlk6Oid-M{GyNFI6QTJ:L3G+
TE1 MlK5RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? NWXoU4ZCPzJiaILz NVT0OZJUSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDUSVEh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKGmwIHPlcIwhfmmjYnnsbZR6KGmwY4XiZZRm\CCob4KgO|IhcHK|IHL5JHNTSiCjc4PhfUwhUUN3ME2xNk44O87:TR?= MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{OTR7NES3Nkc,OzF2OUS0O|I9N2F-
A549 MmeyRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? NUXxRZJjPzJiaILz NED6clVCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFG1OFkh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKGmwIHPlcIwhfmmjYnnsbZR6KGmwY4XiZZRm\CCob4KgO|IhcHK|IHL5JHNTSiCjc4PhfUwhUUN3ME2xN{41Pc7:TR?= M{KxVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNzNEm0OFczLz5|MUS5OFQ4OjxxYU6=
MGC803 NILrPY9CdnSrcILvcIln\XKjdHn2[UBie3OjeR?= M2\Ec|czKGi{cx?= NVfLV|lmSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNS2M5ODNiY3XscJMh[XO|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJINmdGxidnnhZoltcXS7IHnuZ5Vj[XSnZDDmc5IhPzJiaILzJIJ6KFOUQjDhd5NigSxiSVO1NF0yPC5zM988US=> NWS0c3pqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{G0PVQ1PzJpPkOxOFk1PDd{PD;hQi=>
MCF7 NYK5UppkSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= M125VFczKGi{cx?= NF3qU2tCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3DSlch[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKGmwIHPlcIwhfmmjYnnsbZR6KGmwY4XiZZRm\CCob4KgO|IhcHK|IHL5JHNTSiCjc4PhfUwhUUN3ME2yNU46P87:TR?= MmDQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzF2OUS0O|IoRjNzNEm0OFczRC:jPh?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
BCR-ABL / Myc ; 

PubMed: 28128329     


Immunoblotting showing the effect of 2-hour of oridonin treatment on the expression of chaperons.

p-AMPK / AMPK / Glut1 / LC3 ; 

PubMed: 28230866     


Detection of these proteins in a time course experiment after oridonin treatment. Oridonin downregulated p-AMPK and GLUT1 in a time-dependent manner in SW480 cells. 

28128329 28230866
Immunofluorescence
HSF1; 

PubMed: 28128329     


Immunofluorescence detecting HSF1 (Red) in Ph+ leukemia cells. Cells were treated with DMSO or oridonin (K562: 20 μM; KU812 and SUP-B15: 10 μM) for 24 hours, immuno-stained and analyzed by confocal microscopy. 

p65; 

PubMed: 25886043     


NB4 cells were treated with 10 μM oridonin for the indicated times. The intracellular localization of p65 was analyzed by indirect immunofluorescence using anti-p65 antibodies (green). Nuclear DAPI staining (blue) is also shown. Scale bars represent 20 μm. 

28128329 25886043
Growth inhibition assay
Cell viability; 

PubMed: 26496199     


Effects of oridonin on the viability of KYSE-150 cells.

26496199
In vivo

LD50: Mice 35-40mg/kg. [4]

Protocol

Solubility (25°C)

In vitro DMSO 72 mg/mL (197.56 mM)
Ethanol 28 mg/mL (76.83 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+20%PEG 300+ddH2O
For best results, use promptly after mixing.
12.5mg/ml

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 364.43
Formula

C20H28O6

CAS No. 28957-04-2
Storage powder
in solvent
Synonyms Isodonol, Rubescenin
Smiles CC1(CCC(C23C1C(C(C45C2CCC(C4O)C(=C)C5=O)(OC3)O)O)O)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Akt Signaling Pathway Map

Related Akt Products

Tags: buy Oridonin (NSC-250682) | Oridonin (NSC-250682) supplier | purchase Oridonin (NSC-250682) | Oridonin (NSC-250682) cost | Oridonin (NSC-250682) manufacturer | order Oridonin (NSC-250682) | Oridonin (NSC-250682) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID